HUE026440T2 - Composite containing polyunsaturated fatty acids, protein and manganese and / or molybdenum to improve membrane composition - Google Patents

Composite containing polyunsaturated fatty acids, protein and manganese and / or molybdenum to improve membrane composition Download PDF

Info

Publication number
HUE026440T2
HUE026440T2 HUE06824326A HUE06824326A HUE026440T2 HU E026440 T2 HUE026440 T2 HU E026440T2 HU E06824326 A HUE06824326 A HU E06824326A HU E06824326 A HUE06824326 A HU E06824326A HU E026440 T2 HUE026440 T2 HU E026440T2
Authority
HU
Hungary
Prior art keywords
ahol ahol
composition
arta
oligosaccharides
obesity
Prior art date
Application number
HUE06824326A
Other languages
English (en)
Hungarian (hu)
Inventor
Renate Maria Louise Zwijsen
Guenther Boehm
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE026440(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP20050077972 external-priority patent/EP1800675B1/en
Priority claimed from PCT/NL2006/050274 external-priority patent/WO2008054192A1/en
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of HUE026440T2 publication Critical patent/HUE026440T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pediatric Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
HUE06824326A 2005-12-23 2006-12-22 Composite containing polyunsaturated fatty acids, protein and manganese and / or molybdenum to improve membrane composition HUE026440T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20050077972 EP1800675B1 (en) 2005-12-23 2005-12-23 Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
PCT/NL2006/050274 WO2008054192A1 (en) 2006-11-02 2006-11-02 Use of nutritional compositions for preventing disorders

Publications (1)

Publication Number Publication Date
HUE026440T2 true HUE026440T2 (en) 2016-06-28

Family

ID=37964343

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE06824326A HUE026440T2 (en) 2005-12-23 2006-12-22 Composite containing polyunsaturated fatty acids, protein and manganese and / or molybdenum to improve membrane composition

Country Status (14)

Country Link
US (4) US20090186803A1 (enExample)
EP (4) EP1962617A2 (enExample)
JP (1) JP2009521214A (enExample)
CN (1) CN103054048B (enExample)
AU (3) AU2006327995B2 (enExample)
BR (3) BRPI0620466A2 (enExample)
CA (3) CA2634693A1 (enExample)
ES (1) ES2537080T3 (enExample)
HU (1) HUE026440T2 (enExample)
MY (2) MY149164A (enExample)
PL (1) PL1962823T3 (enExample)
PT (1) PT1962823E (enExample)
RU (3) RU2444210C2 (enExample)
WO (3) WO2007073192A2 (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054192A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
CA2697942A1 (en) * 2007-09-07 2009-03-12 Nestec S.A. Range of shelf stable infant foods which include only "naturally contained" sugars and methods for making the same
PT2190304E (pt) 2007-09-17 2012-03-20 Nutricia Nv Formulação nutricional com alto teor energético
CN101909467B (zh) 2007-11-01 2013-04-24 恩兹默泰克有限公司 用于婴儿营养的脂质混合物
RU2478309C2 (ru) * 2007-12-21 2013-04-10 Н.В. Нютрисиа Применение сфингомиелина и неперевариваемых углеводов для нормализации микробиоты кишечника
US20100310725A1 (en) * 2007-12-31 2010-12-09 Kathleen Reidy Nutritionally appropriate menu of food products for children
EP2143341A1 (en) * 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
EP2296494B2 (en) * 2008-06-16 2022-05-18 N.V. Nutricia Infant milk formula with fat gradient
US9491955B2 (en) 2008-08-25 2016-11-15 Brandeis University Balanced myristate- and laurate-containing edible oil
SI2554056T1 (sl) * 2008-09-02 2020-02-28 N.V. Nutricia Prehranski sestavki z lipidnimi globulami velikega premera z oblogo, ki obsega fosfolipide
NZ571856A (en) * 2008-10-09 2011-02-25 Fonterra Corporate Res And Dev Ltd Use of a phospholipid and ganglioside composition for the treatment or prevention of gout
EP2452574A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for young infants
MX2011004921A (es) * 2008-12-08 2011-05-30 Nestec Sa Modulacion de la grasa corporal infantil.
WO2010068086A1 (en) * 2008-12-11 2010-06-17 N.V. Nutricia Nutritional compositions with large lipid globule size
WO2010081604A1 (en) * 2009-01-19 2010-07-22 Nestec S.A. Nutritional composition for infants
WO2010106384A1 (fr) * 2009-03-16 2010-09-23 Societe La Biochimie Appliquee (Solabia) Compositions nutraceutiques, pharmaceutiques ou alimentaires a base de gluco-oligosaccharides
AU2010230362B2 (en) * 2009-04-01 2015-01-15 Société des Produits Nestlé S.A. Reduction of risk of obesity
WO2010119088A2 (en) * 2009-04-15 2010-10-21 Bodo Melnik Milk and milk-based products modified to exhibit a reduced insulinemic index and/or reduced mitogenic activity
WO2011071367A1 (en) 2009-12-11 2011-06-16 N.V. Nutricia Metabolic imprinting effects of structured lipids
PL2353595T3 (pl) 2010-01-19 2016-03-31 Mjn Us Holdings Llc Kompensacja żywieniowa w diecie typu zachodniego
JP5581071B2 (ja) 2010-02-03 2014-08-27 花王株式会社 ミトコンドリア機能向上剤
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
EP2452572A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for infants and children
EP2452573A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
JP2014506891A (ja) * 2011-02-16 2014-03-20 ピヴォタル セラピューティクス インコーポレイテッド 心血管疾患（ＣＶＤ）患者の食事管理のためのω３脂肪酸診断アッセイ
EP2675442A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
WO2012112520A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. A formulations comprising omega 3 fatty acids and an anti obesity agent for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics
CA2827579A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
EP2514435A1 (en) * 2011-04-19 2012-10-24 Nestec S.A. Infant formula for use in the prevention of cardiovascular diseases
WO2012173467A1 (en) 2011-06-16 2012-12-20 N.V. Nutricia Metabolic imprinting effects of specifically designed lipid component
WO2013036102A1 (en) 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with cholesterol
WO2013036103A1 (en) 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with large lipid globules
CN103889240B (zh) * 2011-10-18 2016-09-14 雀巢产品技术援助有限公司 用于增加胰岛素敏感性和/或降低胰岛素抵抗性的组合物
EP2583562A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for infants at risk of obesity or diabetes
EP3384902B1 (en) * 2012-02-17 2020-12-30 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
SE536599C3 (sv) * 2012-04-10 2017-01-10 Hero Ag Näringssammansättning med lågt kalori- och lågt proteininnehåll
WO2013191533A1 (en) * 2012-06-18 2013-12-27 N.V. Nutricia Metabolic imprinting effects of nutrition with large lipid globules comprising milk fat and vegetable fat
WO2014058301A1 (en) * 2012-10-12 2014-04-17 N.V. Nutricia Infant nutrition with lipid globules to increase energy expenditure and metabolic flexibility later in life
US10251928B2 (en) 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
EP2991508A1 (en) * 2013-04-10 2016-03-09 Nestec S.A. Infant formula with a low content of mcfas in specific proportions and a relatively high content of unsaturated fatty acids, and its use in promoting the healthy establishment of cognitive function in infants
RU2648375C2 (ru) * 2013-04-10 2018-03-26 Нестек С.А. Детская смесь с низким содержанием жирных кислот со средней длиной цепи в определенных пропорциях и ее применение при стимуляции и/или обеспечении сбалансированного роста грудных детей
SE537951C2 (sv) * 2013-07-01 2015-12-01 Hero Ag Profylaktisk användning av modersmjölksersättning mot otit
ES2693519T3 (es) 2013-11-01 2018-12-12 N.V. Nutricia Composición lipídica para mejorar la composición corporal durante el crecimiento de recuperación
CN105744845A (zh) * 2013-11-29 2016-07-06 雀巢产品技术援助有限公司 具有磷脂的营养组合物
CN105765587A (zh) * 2013-11-29 2016-07-13 雀巢产品技术援助有限公司 评估婴儿或者幼儿在以后生活中的肥胖症风险的设备、系统和方法
EP3073844B1 (en) * 2013-11-29 2020-01-22 Société des Produits Nestlé S.A. Age-tailored nutritional compositions with a varying protein content
EP3079497B1 (en) 2013-12-12 2019-10-23 Société des Produits Nestlé S.A. Synthetic milk compositions comprising n-6 eicosatrienoic acid and polar lipids for infants younger and older than three months for healthy establishment of cognitive function
MX384125B (es) * 2013-12-12 2025-03-14 Soc Des Produits Nestle S A Star Composiciones sintéticas de leche para infantes menores que tres meses de edad y para infantes y niños mayores que tres meses para asegurar el crecimiento óptimo y prevenir la obesidad.
RU2689550C1 (ru) * 2013-12-12 2019-05-28 Нестек С.А. Искусственные молочные композиции, содержащие полиненасыщенные жирные кислоты (ПНЖК), для содействия здоровому развитию когнитивной функции у младенцев и детей младшего возраста мужского и женского пола
WO2015086170A1 (en) 2013-12-12 2015-06-18 Nestec S.A. Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children
JP6336750B2 (ja) * 2013-12-19 2018-06-06 雪印メグミルク株式会社 脂肪蓄積抑制剤
WO2016050754A1 (en) * 2014-09-30 2016-04-07 Nestec S.A. Nutritional composition with low content of medium-chain fatty acids in specific proportions, and its uses.
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
EP3285602A1 (en) * 2015-04-21 2018-02-28 Enzymotec Ltd. Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation
JP6613661B2 (ja) * 2015-07-08 2019-12-04 花王株式会社 食品に対する内臓脂肪のつきにくさの評価方法
EP3574771B1 (en) 2015-10-15 2022-11-16 N.V. Nutricia Infant formula with special lipid architecture for promoting healthy growth
WO2017129645A1 (en) * 2016-01-26 2017-08-03 Nestec S.A. COMPOSITIONS COMPRISING 2FL AND LNnT TO CONTROL FOOD INTAKE AND GROWTH IN INFANTS OR YOUNG CHILDREN
MX382374B (es) * 2016-04-11 2025-03-13 Soc Des Produits Nestle S A Star Nutrición infantil que proporciona beneficios metabólicos.
WO2017183956A1 (en) * 2016-04-18 2017-10-26 N.V. Nutricia Linoleic acid and alpha-linolenic acid for use for reducing early-life stress induced cognitive decline
BR112018071493A2 (pt) * 2016-04-18 2019-02-19 N.V. Nutricia usos de ácido linoleico (la) e ácido alfa-linolênico (ala) na fabricação de uma composição nutricional, composição nutricional, método para prevenir declínio no funcionamento cognitivo induzido e método para prevenir redução na neurogênese induzida por estresse precoce
EP3471562A4 (en) * 2016-06-15 2020-07-29 Glycom A/S Synthetic compositions comprising human milk oligosaccharides for use the prevention and treatment of disorders
ES2987545T3 (es) 2016-12-09 2024-11-15 Nutricia Nv Composición nutricional para su uso en la mejora del rendimiento cognitivo y/o la prevención del deterioro cognitivo
EP3645024B1 (en) 2017-06-30 2022-09-14 N.V. Nutricia Synbiotic composition for preventing fatty liver disease
EP3645023B1 (en) 2017-06-30 2022-09-14 N.V. Nutricia Synbiotic composition for preventing hyperinsulinemia and insulin resistance
JP2021514608A (ja) * 2018-02-23 2021-06-17 フイルメニツヒ ソシエテ アノニムＦｉｒｍｅｎｉｃｈ Ｓａ 貯蔵安定性のある粉末組成物
US12005083B1 (en) 2019-06-24 2024-06-11 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
US11849747B1 (en) 2019-06-24 2023-12-26 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
CA3158010A1 (en) * 2019-10-29 2021-05-06 Aak Ab (Publ) Nutritional composition comprising milk and egg phospholipids
CN114052243A (zh) * 2020-07-29 2022-02-18 江苏伯克投资管理有限公司 山羊乳提取物的制备及其在全营养特殊医学用途配方食品中的应用
CN112972488B (zh) * 2021-03-02 2022-12-23 青岛农业大学 一种具有抗高尿酸血症活性的岩藻寡糖及其制备方法和应用
CN118102890A (zh) * 2021-10-13 2024-05-28 雀巢产品有限公司 用于改善睡眠的营养组合物
WO2023208925A1 (en) 2022-04-25 2023-11-02 N.V. Nutricia Nutritional composition for use in preventing programmed obesity in female infants

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59187787A (ja) * 1983-04-11 1984-10-24 Meito Sangyo Kk 酵素法スフインゴリン脂質誘導体の製法
ES2033193B1 (es) * 1990-10-30 1994-01-16 Ganadera Union Ind Agro Mezcla grasa para nutricion infantil y de adultos.
US5366914A (en) * 1992-01-29 1994-11-22 Nec Corporation Vertical power MOSFET structure having reduced cell area
US5602109A (en) * 1994-01-10 1997-02-11 Abbott Laboratories Method to enhance the immune system of a human
US6194009B1 (en) * 1996-11-22 2001-02-27 Princeton Nutrition, Llc Refrigeration-shelf-stable ultra-pasteurized or pasteurized infant formula
ID22744A (id) * 1997-02-21 1999-12-09 Abbott Lab Cs Metoda dan komposisi untuk mengurangi pengaruh dari nekrotisasi enterkolitis
JPH10262607A (ja) * 1997-03-28 1998-10-06 Snow Brand Milk Prod Co Ltd 乳幼児用栄養組成物
US6413557B1 (en) * 1997-07-02 2002-07-02 Kyung Ja Lee Soy-containing nutrition supplement and process
ATE230935T1 (de) * 1997-07-22 2003-02-15 Nestle Sa Lipidzusammensetzung für säuglingsnährpräparat und herstellungsverfahren
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US6579551B1 (en) * 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
ATE228779T1 (de) * 1999-01-20 2002-12-15 Nutricia Nv Säuglingsnährpräparat
PL199861B1 (pl) * 1999-04-29 2008-11-28 Nestle Sa Preparat dla niemowląt i sposób wytwarzania preparatu
JP3544493B2 (ja) * 1999-06-10 2004-07-21 雪印乳業株式会社 乳幼児用栄養組成物
US6465714B2 (en) * 1999-11-05 2002-10-15 Arexis Ab Congenic animal models of non-insulin dependent diabetes mellitus
JP2004520318A (ja) * 2000-12-27 2004-07-08 エヌ・ヴイ・ヌートリシア オリゴ糖を含有する健康増進作用を有する栄養組成物
US7090862B2 (en) * 2001-03-30 2006-08-15 Abbott Laboratories Method of improving the antioxidant status of an infant
WO2003005836A2 (en) * 2001-07-10 2003-01-23 Trustees Of Boston University Modified-fat nutritional products useful for preventing or treating obesity
IL150240A (en) * 2002-06-16 2005-07-25 Lipogen Ltd Infant formula supplemented with phospholipids
AU2003251557A1 (en) * 2002-06-28 2004-01-19 Richard C. Theuer Fat compositions for infant formula and methods therefor
SE526943C2 (sv) * 2002-08-26 2005-11-22 Indevex Ab Födoämneskompositionsprodukt
US20050175759A1 (en) * 2004-02-09 2005-08-11 Atul Singhal Newborn infant formulas and feeding methods
US6753350B1 (en) * 2003-03-24 2004-06-22 Bristol-Myers Squibb Company Method to reduce the incidence of intraventricular hemorrhage in preterm infants
US6998392B2 (en) * 2003-04-02 2006-02-14 Mti Meta Tech Inc. Formulation to treat or prevent parasitic infection
RU2346448C2 (ru) * 2003-06-23 2009-02-20 Нестек С.А. Смесь для детей первых месяцев жизни или старше
EP1643862A1 (en) * 2003-06-24 2006-04-12 University of Kansas Medical Center Infant formula
IL158554A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Mimetic lipids as dietary supplements
WO2005063050A1 (en) 2003-12-19 2005-07-14 Abbott Laboratories Method of increasing lean body mass and reducing body fat mass in infants
EP1566439A1 (en) 2004-02-20 2005-08-24 Nestec S.A. Preventing or treating obesity
EP2705849B1 (en) * 2004-07-19 2018-04-04 N.V. Nutricia A preparation for use of aspartate for regulating glucose levels in blood
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
EP1656839A1 (en) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
US20080274945A1 (en) * 2004-11-26 2008-11-06 N.V. Nutricia Infant Nutrition With Protease Inhibitor
CN101087539A (zh) * 2004-12-27 2007-12-12 雀巢技术公司 蛋白质含量降低的婴儿配方的用途
DK1855550T3 (da) * 2005-02-28 2012-01-16 Nutricia Nv Næringspræparat med probiotika
KR101355850B1 (ko) * 2005-03-08 2014-01-27 네스텍 소시에테아노님 식품용 압출 고형 제품
US20070191264A1 (en) * 2005-05-05 2007-08-16 Bristol-Myers Squibb Company, A Delaware Corporation Methods for inhibiting the growth of bacteria

Also Published As

Publication number Publication date
AU2006327995A1 (en) 2007-06-28
AU2006327995B2 (en) 2012-09-13
US20160175393A1 (en) 2016-06-23
BRPI0620465A2 (pt) 2011-11-16
PL1962823T3 (pl) 2015-08-31
MY149164A (en) 2013-07-31
WO2007073192A3 (en) 2007-08-16
MY162091A (en) 2017-05-31
AU2006327996B2 (en) 2012-03-29
JP2009521214A (ja) 2009-06-04
US20090186803A1 (en) 2009-07-23
EP2305049A1 (en) 2011-04-06
WO2007073194A3 (en) 2008-06-12
US20120121757A1 (en) 2012-05-17
EP1973424B1 (en) 2019-09-11
US20110136732A1 (en) 2011-06-09
CA2634117A1 (en) 2007-06-28
RU2008130365A (ru) 2010-01-27
RU2417712C2 (ru) 2011-05-10
WO2007073193A2 (en) 2007-06-28
RU2444210C2 (ru) 2012-03-10
US8871218B2 (en) 2014-10-28
CA2634895A1 (en) 2007-06-28
CN103054048A (zh) 2013-04-24
AU2006327996A1 (en) 2007-06-28
WO2007073193A3 (en) 2007-08-16
BRPI0620466A2 (pt) 2011-11-16
RU2008130370A (ru) 2010-01-27
ES2537080T3 (es) 2015-06-02
CA2634693A1 (en) 2007-06-28
AU2006327997A8 (en) 2008-07-31
PT1962823E (pt) 2015-06-29
RU2008130367A (ru) 2010-01-27
CN103054048B (zh) 2014-11-19
WO2007073194A2 (en) 2007-06-28
EP1973424A2 (en) 2008-10-01
WO2007073192A2 (en) 2007-06-28
BRPI0620451A2 (pt) 2011-04-12
EP1962617A2 (en) 2008-09-03
EP1962823B1 (en) 2015-03-04
EP1962823A2 (en) 2008-09-03
AU2006327997A1 (en) 2007-06-28
AU2006327997B2 (en) 2012-03-29
RU2414905C2 (ru) 2011-03-27

Similar Documents

Publication Publication Date Title
AU2006327997B2 (en) Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
CN101360489B (zh) 用于改善膜组成的包含多不饱和脂肪酸、蛋白质和锰和/或钼的组合物
EP2542101B1 (en) Modulation of post-prandial fat absorption
NZ569264A (en) Infant nutritional compositions for preventing obesity comprising linoleic acid
WO2013036104A1 (en) Infant nutrition for regulating food intake later in life
US20170151175A1 (en) Infant nutrition with lipid globules to increase energy expenditure and metabolic flexibility later in life